Ehave Launches Conners® Suite of ADHD Assessment Tools for Ehave Connect

By June 19, 2017Press Releases

Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced the integration and release of the Conners 3® and Conners Comprehensive Behaviour Rating Scales™ (CBRS®) suite of assessments for ADHD diagnosis into Ehave Connect, a cloud-based, digital informatics platform designed to aid in the diagnosis and treatment of mental health disorders. Created by Ehave’s partner Multi-Health Systems Inc. (MHS), an international healthcare technology developer of scientifically validated psychological assessments with products sold in more than 75 countries and translated into more than 50 languages, this initial content represents the first third-party tools and assessments to be offered digitally through Ehave Connect and demonstrate the platform’s ability to rapidly integrate new partners into the platform.

Regularly assessing patient symptoms is a critical part of the multimodal management plan for ADHD and other mental health conditions. After obtaining baseline information on the patient’s impairment at school, work, or other settings before carrying out the management plan, adjustments can be made as needed as the plan is carried out. With this integration of the Conners suite, Ehave Connect will enable healthcare professionals to easily add new patients, register users such as teachers and doctors, assign surveys via the cloud, seamlessly integrate patient data, and provide secure, gated access to patient profiles limited to parents, adult patients and healthcare providers.

Hazel Wheldon, President and Chief Operating Officer of MHS, Inc., said, “MHS is thrilled to add EHave Connect as a digital provider of our tools. The EHave Connect solution offers clients an integrated solution for connecting assessment data with other patient data to provide a seamless end to end solution.”

“We will continue to integrate and validate MHS’s extensive offering of clinically validated mental health assessments. The successful integration and launch of the Conners suite for ADHD is just the beginning of this process and an excellent case study for the immense value Ehave Connect can bring to patients, caregivers, mental health professionals and partners,” said Prateek Dwivedi, CEO of Ehave. “Ehave is committed to providing an all-inclusive selection of validated mental health assessment and remediation tools. The seamless delivery of MHS’s assessment tools alongside our MegaTeam remediation apps, coupled with our outcomes tracking is the perfect example of how we intend to streamline the mental healthcare experience, making the process simpler for both mental healthcare providers and patients.”

According to the Centers for Disease Control and Prevention, the rate of ADHD diagnosis in children has steadily risen from 1997 through 2011, reaching 11.0% of children ages 5-17, highlighting the need for an easy and efficient diagnosis and management platform. In addition to childhood diagnosed ADHD, a comprehensive 2006 National Comorbidity Survey sponsored by the National Institute of Mental Health found rates of ADHD in adults to be 4.4%, with a majority of those cases going undiagnosed and untreated.  Ehave is positioning itself to fulfill this need for easy and efficient ADHD diagnosis, simplifying the process for both patient and provider.

A leading technology company focused on innovative digital delivery of data analysis and scientifically validated assessments for more than 30 years, Multi-Health Systems Inc. (MHS) serves clients in corporate, clinical, educational, public safety, government, military, pharmaceutical, and research settings. With offices in North America and partners around the world, MHS is dedicated to improving the lives of individuals and communities through technology. MHS has developed leading products such as the Emotional Quotient Inventory (EQ-i 2.0®), the Conners™ suite of ADHD assessments, and the Level of Service™ suite of assessments. MHS has been named one of Canada’s Best Managed Companies since 2013. The best managed designation is a recognized symbol of excellence for Canadian businesses. Additionally, in 2016, MHS won Canada’s 10 Most Admired Corporate Cultures award in the Growth and Small Cap category.  For more information about MHS, please visit www.mhs.com.

Ehave is empowering the mental healthcare community with a next-generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave’s mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with MedReleaf.

Joshua Drumm, Ph.D.
jdrumm@tiberend.com
(212) 375-2664

Janine McCargo
jmccargo@tiberend.com
(646) 604-5150

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

SUBSCRIBE TO RECEIVE NEWS AND INSIGHTS BY EMAIL